Cancers,
Journal Year:
2025,
Volume and Issue:
17(2), P. 282 - 282
Published: Jan. 17, 2025
Chimeric
antigen
receptor
T-cell
(or
CAR-T)
therapy
and
bispecific
antibodies
(BsAbs)
have
revolutionized
the
treatment
of
hematologic
malignancies,
offering
new
options
for
relapsed
or
refractory
cases.
However,
these
therapies
carry
risks
early
complications,
such
as
cytokine
release
syndrome
(CRS)
immune
effector
cell-associated
neurotoxicity
(ICANS),
delayed
issues
like
graft-versus-host
disease
(GVHD),
infections,
secondary
cancers.
Effective
management
requires
diagnosis
using
advanced
biomarkers
imaging,
along
with
prompt
interventions
involving
immunosuppressants,
corticosteroids,
inhibitors.
A
multidisciplinary
approach
is
essential,
integrating
hematologists,
oncologists,
infectious
specialists,
emerging
strategies
targeted
biologics
personalized
medicine
showing
promise
in
balancing
efficacy
toxicity
management.
Ongoing
research
critical
to
refine
diagnostics
treatments,
ensuring
that
not
only
extend
survival
but
also
improve
patients'
quality
life.
This
review
provides
insights
healthcare
professionals
quickly
recognize
treat
complications
CAR-T
BsAbs
therapies.
By
focusing
on
detection
through
imaging
outlining
timely
therapeutic
interventions,
it
aims
equip
care
team
knowledge
necessary
manage
challenges
treatments
effectively,
ultimately
optimizing
patient
outcomes.
Lymphatics,
Journal Year:
2025,
Volume and Issue:
3(1), P. 2 - 2
Published: Jan. 22, 2025
Multiple
myeloma
is
an
incurable
hematologic
malignancy
arising
from
plasma
cells.
The
uncontrolled
growth
of
monoclonal
cells
leads
to
abnormal
overproduction
immunoglobulins.
recommended
course
treatment
for
MM
according
disease
progression
and
responses
therapeutic
intervention,
highlighting
the
necessity
multiple
options
that
alleviate
different
parts
MM.
This
comprehensive
review
provides
insights
into
current
treatments
how
take
preventative
prognostic
measures.
In
advanced
MM,
osteoporosis
a
common
symptom
originates
lack
regulation
in
osteoclast
activity
bone
resorption.
Bisphosphonates
such
as
zoledronic
acid
pamidronate
along
with
antibodies
denosumab
hinder
function
aid
reducing
risk
fractures
patients
For
targeted
therapy
approaches,
proteasome
inhibitors
impede
protein
degradation
pathways
cause
accumulation
misfolded
proteins
promoting
cancer
cell
proliferation
CAR-T
another
can
utilize
T
target
isolate
Overall,
this
highlights
frontrunners
those
diagnosed
Deleted Journal,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Jan. 16, 2025
Immuntherapien
haben
die
Behandlung
des
multiplen
Myeloms
grundlegend
verändert.
Die
Einführung
von
monoklonalen
Antikörpern
wie
Daratumumab
markierte
einen
ersten
Durchbruch
und
etablierte
diese
Wirkstoffklasse
in
der
Erstlinientherapie.
Neuere
Ansätze
CAR-T-Zellen
bispezifische
Antikörper
nutzen
das
enorme
zytotoxische
Potenzial
T‑Zellen
zur
gezielten
Eliminierung
Krebszellen
zeigen
beeindruckende
Ergebnisse.
So
ist
Ciltacabtagen-Autoleucel
(Cilta-Cel)
bei
Patienten
mit
Lenalidomid-refraktärer
Erkrankung
bereits
ab
zweiten
Therapielinie
zugelassen.
Bispezifische
bieten
darüber
hinaus
auch
nach
CAR-T-Zell-Therapie
vielversprechende
Therapieoptionen.
Besonders
Aussicht,
durch
eine
einmalige
Infusion
langanhaltende
tiefe
Remissionen
zu
erzielen,
könnte
Zukunft
therapiefreien
Intervallen
für
Patient:innen
führen.
Allerdings
beinhalten
neue
Herausforderungen.
Zum
Beispiel
wurde
erhöhte
Infektionsrate
unter
BCMA-adressierenden
Therapien
beobachtet,
engmaschige
Überwachung
Substitution
polyvalenten
Immunglobulinen
erfordert.
Ebenso
Antigenverlust
ein
potenzielles
Problem,
insbesondere
sequenziellen
berücksichtigt
werden
muss.
Im
vorliegenden
Artikel
Chancen,
entstehen,
erörtert
gleichzeitig
Herausforderungen
Anforderungen,
Therapieplanung
sollten,
angesprochen.
Expert Opinion on Biological Therapy,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Feb. 8, 2025
Introduction
Bispecific
antibody
therapies,
primarily
targeting
B-cell
maturation
antigen
(BCMA),
have
shown
remarkable
outcomes
in
the
treatment
of
heavily
pretreated
patients
with
multiple
myeloma
(MM).
However,
there
are
no
current
head-to-head
trials
informing
practice
for
selection
or
sequencing
optimal
T
cell
redirection
strategies
later
lines
therapy.
Linvoseltamab
is
a
novel
BCMA-targeted
bispecific
that
was
recently
evaluated
phase
1/2
LINKER-MM1
trial
and
currently
pending
formal
regulatory
approval.
Cancers,
Journal Year:
2025,
Volume and Issue:
17(4), P. 653 - 653
Published: Feb. 14, 2025
Multiple
myeloma
(MM)
is
a
complex
and
heterogeneous
hematologic
malignancy
characterized
by
clonal
evolution,
genetic
instability,
interactions
with
supportive
tumor
microenvironment.
These
factors
contribute
to
treatment
resistance,
disease
progression,
significant
variability
in
clinical
outcomes
among
patients.
This
review
explores
the
mechanisms
underlying
MM
including
epigenetic
changes
that
drive
role
of
bone
marrow
microenvironment
supporting
growth
immune
evasion,
impact
genomic
instability.
We
highlight
critical
insights
gained
from
single-cell
technologies,
such
as
transcriptomics,
genomics,
multiomics,
which
have
enabled
detailed
understanding
heterogeneity
at
cellular
level,
facilitating
identification
rare
cell
populations
drug
resistance.
Despite
promise
advanced
remains
an
incurable
challenges
remain
their
application,
high
costs,
data
complexity,
need
for
standardized
bioinformatics
ethical
considerations.
emphasizes
importance
continued
research
collaboration
address
these
challenges,
ultimately
aiming
enhance
personalized
strategies
improve
patient
MM.
Advances in Radiation Oncology,
Journal Year:
2025,
Volume and Issue:
unknown, P. 101764 - 101764
Published: March 1, 2025
Proton
therapy
(PT)
has
distinct
advantages
in
its
ability
to
precisely
target
tumors
while
avoiding
adjacent
normal
tissues.
However,
the
distal
edge
effects
of
PT
constrain
application.
This
study
investigated
brain
tissue
response
regions
protons
and
compared
it
with
effect
photons.
The
occurrence
damage
from
photons
at
was
a
murine
model.
Bragg
peak
treatment
plans
for
models
were
optimized.
Hematoxylin
eosin
immunofluorescence
staining
performed
along
margin.
In
addition,
approximate
distance
neuronal
sites
calculated.
Furthermore,
small-molecule
inhibitor
studied
inhibit
microglia
activation.
injury
model
successfully
established.
Reactive
gliosis
granulovacuolar
degeneration
observed
right
hemisphere
proton
irradiation
group.
Neuronal
injuries
multiple
locations
(the
frontal
lobe,
thalamus,
cerebral
cortex)
border,
but
no
injured
neurons
detected
vertical
photon
exposed
areas.
Meanwhile,
severe
neural
seen
horizontal
irradiation.
At
(0.4633
±
0.01856
cm),
abnormal
morphology
accumulated.
IBA1
CD68
revealed
activated
corresponding
sites,
indicating
their
involvement
irradiation-induced
damage.
Activated
not
irradiation,
whereas
many
Moreover,
asparagine
endopeptidase
inhibitors
administered
via
intraperitoneal
injection
significantly
reduced
active
thalamus
cortex
alleviated
demonstrated
that
radiation
induces
accumulation
edge.
Targeting
may
play
protective
role
radiation.
